Business
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of
About this update from Prelude Therapeutics Incorporated
[{"type":"image","alt":"Prelude Therapeutics, Incorporated","displaySize":"","headline":null,"caption":"Prelude Therapeutics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9HVZo7WrFLmSMiAVkGF1.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555","width":300,"height":103}},"lazy":false},{"type":"text","content":"First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms","length":138,"tagName":"p"},{"type":"text","content":"PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026","length":102,"tagName":"p"},{"type":"text","content":"First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload","length":127,"tagName":"p"},{"type":"text","content":"JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of MPN patients","length":143,"tagName":"p"},{"type":"text","content":"WILMINGTON, Del., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a precision oncology company, presented earlier today the first preclinical data on its JAK2V617F mutant selective JH2 inhibitors and additional preclinical data from its mCALR-targeted degrader antibody conjugate (DAC) discovery program. Both oral presentations took place at the American Society of Hematology (ASH) 67th Annual Meeting in Orlando, FL. These presentations can be found at Publications - Prelude Therapeutics.","length":557,"tagName":"p"},{"type":"text","content":"“Since JAK2V617F was first identified as a major driver mutation in JAK2 enzyme in myeloproliferative neoplasms two decades ago, our industry has been searching for an inhibitor that can selectively target the mutant JAK2 enzyme without disrupting normal JAK2 function” stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “We are proud to have made significant advances in the discovery of such molecules and to share preclinical data demonstrating that...